SCHEMBL3584407

SCHEMBL3584407

CCOC(=O)c1sc(NC(=O)c2ccccc2)nc1C

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.80
KDM4E B2RXH2 5/20 0.80
HTT P42858 1/20 0.80
CSNK1D P48730 1/20 0.79
MEN1 O00255 1/20 0.79
PKM P14618 1/20 0.79
KMT2A Q03164 1/20 0.79
KCNH2 Q12809 1/20 0.79
ALDH1A1 P00352 9/20 0.78
NPC1 O15118 7/20 0.78
NPSR1 Q6W5P4 4/20 0.78
RXFP1 Q9HBX9 3/20 0.78
TP53 P04637 1/20 0.77
LMNA P02545 3/20 0.73
RAB9A P51151 5/20 0.69
HPGD P15428 5/20 0.69
MAPT P10636 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877171 0.95 ALDH1A1 (0.75) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL3582251 0.89 SMN1; SMN2 (1.00) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL4636708 0.87 TP53 (0.67) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL3580925 0.86 KMT2A (0.78) SMN1; SMN2KDM4EHTTMEN1KMT2A
SCHEMBL31558296 0.85 ALDH1A1 (0.75) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL16607174 0.85 ALDH1A1 (0.75) SMN1; SMN2KDM4EHTTMEN1KMT2A
SCHEMBL3586012 0.84 ALDH1A1 (1.00) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL8109639 0.84 ALDH1A1 (0.73) SMN1; SMN2KDM4EHTTCSNK1DMEN1
SCHEMBL3582729 0.84 NPC1 (0.73) SMN1; SMN2KDM4EMEN1PKMKMT2A
SCHEMBL4920930 0.84 SMN1; SMN2 (0.78) SMN1; SMN2KDM4EHTTCSNK1DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541457-B2 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2013-09-24 US disclosed
US-8541457-B2 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2013-09-24 US disclosed
US-8541457-B2 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors XENON PHARMACEUTICALS INC. (CA) 2013-09-24 US disclosed
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2013-04-18 US disclosed
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2013-04-18 US disclosed
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2013-04-18 US disclosed
EP-2540296-A1 Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2013-01-02 EP disclosed
EP-2540296-A1 Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors Xenon Pharmaceuticals Inc. (CA) 2013-01-02 EP disclosed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 US disclosed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 US disclosed
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2010-06-17 US disclosed
EP-2029138-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2009-03-04 EP disclosed
WO-2007130075-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-11-15 WO disclosed
WO-2007130075-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152187-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 SMN1; SMN2 1323/4885KDM4E 431/4885HTT 1544/4885
US-20130096056-A1 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS SCD, SCD5, ACAT1 SMN1; SMN2 1277/4885KDM4E 434/4885HTT 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.